A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

To join this study, you generally need to be at least 18 years old and have a confirmed diagnosis of classic follicular lymphoma that hasn't been treated before. Your general health should be good enough for you to take part, and your lymphoma needs to be at a stage where treatment is recommended. Doctors will check your organ function (like your liver, kidneys, and heart) to make sure you're healthy enough.

There are also certain reasons why someone might not be able to join. For example, if your follicular lymphoma is a specific rare type, or if doctors suspect it has changed into a more aggressive lymphoma, you wouldn't be eligible. You also can't have certain other medical conditions, a history of lymphoma in the brain or spine, or allergies to the study medications. If you have any serious infections, you also wouldn't be able to participate straight away.

If you decide to take part, you'll first go through a screening process to see if the study is right for you. This will involve detailed health checks and tests. Once eligible, you'll be randomly assigned to one of several treatment groups. This means you might receive the new drug combination or one of the standard treatments. Your doctors will carefully monitor your health throughout the study, which will involve regular visits, blood tests, scans, and other assessments to track your progress and check for any side effects.

Participation could last for a significant period, involving treatment cycles and then follow-up appointments. The exact duration will depend on your assigned treatment and how you respond. The study team will provide you with a clear schedule of visits and what to expect at each stage. You will also receive the study medication, with clear instructions on how and when to take it.